@article {591216,
	title = {Visual Acuity Outcomes of the Boston Keratoprosthesis Type 1: Multicenter Study Results.},
	journal = {Am J Ophthalmol},
	volume = {162},
	year = {2016},
	month = {2016 Feb},
	pages = {89-98.e1},
	abstract = {PURPOSE: To report logarithm of the minimal angle of resolution (logMAR) visual outcomes of the Boston keratoprosthesis type 1. DESIGN: Prospective cohort study. METHODS: Preoperative, intraoperative, and postoperative parameters of 300 eyes of 300 patients who underwent implantation of a Boston keratoprosthesis type 1 device between January 2003 and July 2008 by 1 of 19 surgeons at 18 medical centers were collected. RESULTS: After an average of 17.1 {\textpm} 14.8\&nbsp;months, visual acuity improved significantly (P \&lt; .0001) to a mean final value of 0.89 {\textpm} 0.64 (20/150). There were also significantly fewer eyes with light perception (6.7\%; n\&nbsp;= 19; P \&lt; .0001), although 3.1\% (n\&nbsp;= 9) progressed to no light perception. There was no association between age (P\&nbsp;= .08), sex (P\&nbsp;= .959), operative side (P\&nbsp;= .167), or failure (P\&nbsp;= .494) and final visual acuity. The median time to achieve 20/200 visual acuity was 1\&nbsp;month (95\% confidence interval 1.0-6.0) and it was retained for an average of 47.8\&nbsp;months. Multivariate analysis, controlling for preoperative visual acuity, demonstrated 2 factors associated with final visual outcome: chemical injury was associated with better final vision (P\&nbsp;= .007), whereas age-related macular degeneration was associated with poorer vision (P \&lt; .0001). CONCLUSIONS: The Boston keratoprosthesis type 1 is an effective device for rehabilitation in advanced ocular surface disease, resulting in a significant improvement in visual acuity. Eyes achieved a mean value of 20/150 (0.89 {\textpm} 0.64 logMAR units) after 6\&nbsp;months and this was relatively stable thereafter. The best visual prognosis is observed in chemical injury eyes, whereas the\&nbsp;worst prognosis is in aniridia, although the latter has limited visual potential.},
	issn = {1879-1891},
	doi = {10.1016/j.ajo.2015.10.023},
	author = {Rudnisky, Christopher J and Belin, Michael W and Guo, Rong and Ciolino, Joseph B and Boston Type 1 Keratoprosthesis Study Group}
}
